📈 Jumpstart Signal Watchlist — October 26, 2026

🏢 What they do: Aveanna Healthcare provides in-home nursing and therapy, home health and hospice care, and medical supplies such as enteral nutrition products. Its services support children and adults with complex medical needs.
- 🎯 Current $13.18 is 8% below 3yr high $14.38 · ⏳ SMA200 $9.19 (current price $13.18 is above) · 💰 Market Cap $2.9B
- AVAH shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 38% (>20%); ROE 96% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.27 (<1.5).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×3).
✅ Raymond James initiates Aveanna Healthcare stock coverage with Strong Buy — Investing.com.
🤖 Raymond James initiated coverage with a Strong Buy rating and a $15 price target, citing healthy demand and potential growth drivers. The article is dated September 28, within the requested period.
✅ Is Aveanna Healthcare Holdings (AVAH) Still Below Fair Value Following Its Zacks Upgrade? — Yahoo Finance.
🤖 The article reports a Zacks Rank of #2 and a roughly 14.1% increase in full-year earnings estimates over the prior three months. It also notes the shares’ recent gains and a fair-value estimate above the cited closing price.
✅ Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) Stock Has Average Target Price of $14.06 According to Analysts — MarketBeat.
🤖 The article describes a Moderate Buy consensus and an average price target above the cited share price, alongside previously reported earnings and revenue that exceeded estimates. The earnings results themselves predate the requested period, so the positive assessment here is based on the reported analyst consensus.
🍭 Bonus (B): 0/10 — Home Health Care Services

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $14.72 is 4% below 3yr high $15.26 · ⏳ SMA200 $10.74 (current price $14.72 is above) · 💰 Market Cap $995M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 327% (>20%); ROE 24% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.06 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (6.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 62 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×1).
✅ Bioventus Inc. (NASDAQ:BVS) Stock Has Average Target Price of $16.80 — MarketBeat.
🤖 The October 23 article reports that all six covering analysts rate Bioventus a Buy, with an average 12-month price target of $16.80. It also notes Weiss Ratings upgraded the stock from Hold to Buy on October 8; the article includes older earnings and institutional ownership information, which is not a new catalyst.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $11.04 is 13% below 3yr high $12.66 · ⏳ SMA200 $9.34 (current price $11.04 is above) · 💰 Market Cap $1.9B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? — Zacks.
🤖 The article discusses Vir’s collaboration with Gilead to develop three solid-tumor T-cell engagers. The deal includes upfront and potential milestone payments, plus royalties, providing funding and commercial potential for Vir’s oncology platform.
✅ Vir Biotechnology Shares Jump on Gilead Cancer Collaboration — MarketWatch.
🤖 Vir shares rose after the company announced a Gilead collaboration covering three T-cell engager candidates. The agreement offers upfront consideration, potential milestone payments of up to $1.74 billion, and royalties.
✅ Vir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal — Reuters.
🤖 The partnership gives Vir upfront and potential milestone payments, as well as royalties, for developing candidates that Gilead can advance and commercialize. The deal adds financial support and validation for Vir’s cancer-treatment platform.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Red Violet, Inc. provides identity intelligence software and data solutions for identity verification, fraud detection and prevention, risk mitigation, investigations, due diligence, customer acquisition, and asset recovery. Its products include idiCORE and FOREWARN.
- 🎯 Current $80.12 is 1% below 3yr high $80.80 · ⏳ SMA200 $56.53 (current price $80.12 is above) · 💰 Market Cap $1.1B
- RDVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 89% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0).
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×3 ❌×1; showing 3 of 4).
✅ FOREWARN Introduces Community Alerts, Activating a Nationwide Agent Network as a Real-Time Safety Resource — GlobeNewswire.
🤖 Red Violet subsidiary FOREWARN launched Community Alerts, a new feature that lets real estate professionals flag concerning phone numbers for other users. The product launch expands the company’s safety offerings and network capabilities.
✅ red violet Debuts on Fortune’s 2026 Fastest-Growing Companies List at No. 43 — GlobeNewswire.
🤖 Red Violet ranked No. 43 on Fortune’s 2026 list, with the recognition citing sustained growth in revenue, profits, and shareholder returns. This is a favorable signal about the company’s recent performance.
❌ Red Violet (NASDAQ:RDVT) Stock Rating Lowered by Zacks Research — MarketBeat.
🤖 Zacks Research lowered its rating on Red Violet from strong buy to hold. The downgrade is a negative analyst signal, although the article notes the broader analyst consensus remains favorable.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: Nutanix provides software for running and managing applications and data across private data centers, edge locations, and public clouds. Its platform combines software-defined computing, storage, virtualization, and cloud-management tools to support hybrid and multicloud environments.
- 🎯 Current $72.71 is 12% below 3yr high $83.07 · ⏳ SMA200 $52.21 (current price $72.71 is above) · 💰 Market Cap $16.5B
- NTNX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 3007% (>20%); Revenue growth 16% (>15%); ROE 214% (>15%); Low LT D/E 0.00 (<1.0).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Nutanix gains as Guggenheim starts coverage at Buy amid VMware share gains — Yahoo Finance.
🤖 Guggenheim initiated coverage with a Buy rating and a $100 price target, citing Nutanix’s opportunity to gain share from VMware and potential growth in cloud and AI infrastructure. The article reports the shares rose 1.6% following the initiation.
✅ Guggenheim initiates Nutanix stock with buy rating on VMware opportunity — Investing.com.
🤖 Guggenheim began coverage with a Buy rating and a $100 price target, pointing to Nutanix’s position as a VMware alternative and forecasting revenue growth above consensus. The article also cites recent analyst target increases, though these are not separate news items here.
✅ Nutanix and Netris Announce Strategic Collaboration to Deliver a Multitenant Infrastructure Stack from Compute to Network for Neoclouds and NVIDIA Cloud Partner Environments — Yahoo Finance.
🤖 Nutanix and Netris announced a jointly engineered infrastructure stack for neoclouds and enterprise environments. The collaboration could expand Nutanix’s reach in cloud infrastructure.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: Karat Packaging Inc. manufactures and distributes disposable foodservice products used by restaurants and other foodservice businesses. Its products include food and take-out containers, cups, lids, cutlery, straws, tableware, bags, and compostable packaging, along with related supplies and services.
- 🎯 Current $54.35 is 1% below 3yr high $54.68 · ⏳ SMA200 $35.02 (current price $54.35 is above) · 💰 Market Cap $1.1B
- KRT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (13.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 170% (>20%); ROE 30% (>15%); Low LT D/E 0.00 (<1.0).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Full Transcript: Karat Packaging Q2 2026 Earnings Call — Benzinga.
🤖 The transcript describes record quarterly sales, strong online growth, and four new chain accounts. Management also expected low-double-digit sales growth for the rest of 2026, though the quarter’s unusually high margin benefited from a tariff refund.
✅ Karat Packaging stock hits all-time high at 55.38 USD — Investing.com.
🤖 The article reports KRT reached an all-time high, reflecting strong recent share-price performance. It also notes that second-quarter profit growth was boosted by a substantial tariff refund, while revenue was slightly below one analyst forecast.
✅ Zacks Industry Outlook Highlights Avery Dennison, AptarGroup and Karat Packaging — Zacks.
🤖 The article highlights Karat Packaging’s record second-quarter sales, solid customer demand, and 23.6% year-over-year growth in online sales. It also notes the addition of four chain accounts.
🍭 Bonus (B): 0/10 — Rubber & Plastics Products

🏢 What they do: Five9, Inc. provides cloud contact center software, including its Intelligent CX platform for managing customer interactions across voice and digital channels like chat, email, SMS, and social media. Its products also include AI, automation, analytics, and workforce optimization tools that help businesses run customer service and sales operations.
- 🎯 Current $37.74 is 56% below 3yr high $85.47 · ⏳ SMA200 $23.76 (current price $37.74 is above) · 💰 Market Cap $2.8B
- FIVN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 300% (>20%); Low LT D/E 0.25 (<1.0); PEG ratio 0.18 (<1.5).
⏰ Entry (E): 4/20
- 🔔 Strong above EMA21 (7.9%)
- 🔔 Strong above EMA50 (13.0%)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 6/10
- 🗞️ News sentiment is positive (mixed coverage; ✅×2 ❌×1 ⚪️×2).
✅ Five9 Named a Leader in the 2026 Gartner® Magic Quadrant™ for Contact Center as a Service for the Ninth Time — Business Wire.
🤖 Five9 announced it was named a Gartner Leader in CCaaS for the ninth time, recognized for its vision and execution. The recognition may support the company’s competitive positioning and customer confidence.
✅ Five9股价今日大涨6.5%，分析师看涨浪潮持续推动股价走高 — Investing.com.
🤖 The article attributes Five9’s share-price rise to bullish analyst actions, including UBS raising its price target to $48 and maintaining a Buy rating, citing potential growth from large financial-services contracts. It also notes a reseller partnership, though the reported stock move and some context are market-specific.
❌ Five9, Inc. (NASDAQ: FIVN) Investor Reminder: Schubert Jonckheer & Kolbe LLP Investigating Possible False Statements Following 26% Stock Drop and Key Court Ruling — PR Newswire.
🤖 A law firm said it is investigating potential wrongdoing after a court allowed key claims in a securities-fraud lawsuit against Five9 and former executives to proceed. The article recalls the 26% share-price drop following disappointing 2024 results and a guidance reduction, adding litigation and reputational risk.
⚪️ Five9 (FIVN) Stock Looks About Right On Fresh Gartner Leader Recognition — Yahoo Finance.
🤖 The article discusses Five9’s Gartner recognition and AI-driven platform as factors investors may consider when assessing future growth and profitability. It does not report a distinct new financial or operational catalyst beyond the recognition.
⚪️ Five9 Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) — Business Wire.
🤖 Five9 disclosed restricted stock unit awards covering 93,116 shares for five new employees. The awards are a routine hiring-related equity disclosure, with no material business or financial update reported.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: # RingCentral, Inc. (RNG) RingCentral is a cloud-based business communications platform that provides unified communications, contact center solutions, workforce engagement management, video collaboration, and messaging services to over 500,000 businesses.
- 🎯 At/above 3yr high $86.31 (current $86.31) · ⏳ SMA200 $48.11 (current price $86.31 is above) · 💰 Market Cap $3.2B
- RNG shows decent technicals supported by positive sentiment.

💎 Quality (Q): 38/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 3321% (>20%); PEG ratio 0.00 (<1.5).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA21 (9.3%)
- 🔔 Strong above EMA50 (17.9%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ RingCentral (RNG) shares skyrocket, what you need to know — Yahoo Finance.
🤖 Shares rose 6.4% after RingCentral reported third-quarter results and raised its full-year 2026 outlook. The higher revenue, earnings, margin, and free-cash-flow guidance supports a positive view.
✅ RingCentral (RNG) Gains Fresh Attention As AI Progress And Higher Guidance Test Valuation — Yahoo Finance.
🤖 The article highlights stronger-than-expected third-quarter results, a higher full-year outlook, and AI partnerships. It also notes softer billings expectations and insider selling, which temper the positive picture.
✅ RingCentral Soars 7% on Its “Strongest Topline Quarter” as Analysts More Than Double Price Target — Yahoo Finance.
🤖 Morgan Stanley more than doubled its price target to $91 after describing RingCentral’s quarter as its strongest topline performance, while retaining an Equal Weight rating. UBS and Jefferies also raised their targets, though both kept neutral ratings.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)